Surgical and Oncologic Outcomes After Robotic Nipple Sparing Mastectomy and Immediate Reconstruction
- Conditions
- Breast CancerBRCA1 MutationPostoperative ComplicationsRecurrenceBRCA2 MutationBreast NeoplasmsSurgerySurgery--Complications
- Interventions
- Procedure: Robotic nipple sparing mastectomy
- Registration Number
- NCT04108117
- Lead Sponsor
- Severance Hospital
- Brief Summary
Robotic mastectomy with immediate reconstruction was introduced by Toesca et al. in 2015. Since then, several studies have reported the safety and feasibility of robotic nipple-sparing mastectomy with immediate reconstruction. However, most studies were conducted by single centers and had small samples. Furthermore, there is a lack of studies comparing surgical and oncologic outcomes between robotic nipple-sparing mastectomy and conventional nipple-sparing mastectomy. For this reason, this study evaluates surgical and oncologic outcomes of robotic nipple-sparing mastectomy with immediate reconstruction using international multi-center data.
- Detailed Description
This study is an international multi-center pooled analysis using prospective and retrospective studies to evaluate surgical and oncologic outcomes of robotic nipple-sparing mastectomy with immediate reconstruction.
Raw data for robotic or conventional nipple-sparing mastectomy from Severance Hospital, Samsung Medical Center, the European Institute of Oncology, Changhua Christian Hospital, and Gustave Roussy is collected. Among them, Severance Hospital takes the lead at performing analysis from the data. Storage and disposal of patients' records are managed by each researcher. In the analysis process, although the collaborators can request records from Severance Hospital if necessary, they are only supposed to be provided computerized data which were originally clinical data from patients who already ended treatments. In this case, individual identifying data and medical records are not shown.
Clinicopathologic variables including operation times, hospital stay, medical history, smoking history, family history, BMI, menopausal status, specimen weight, TNM stage, grade, histological type, estrogen receptor, progesterone receptor, HER2, Ki 67, and perivascular involvement are analyzed.
Postoperative complications within 30 days are collected and classified by the Clavien-Dindo grade. Locoregional recurrence-free survival and local and systemic recurrences are examined. Patients whose data have been retrospective for at least one month are to be examined.
Patient's and surgeon's satisfaction using Breast Q is evaluated. Categorical variables are examined using the chi-square test or Fisher's exact test if indicated.
Continuous variables are examined using the independent t-test or ANOVA if indicated.
The estimated sample size from the four institutions is about 300 cases for robotic nipple-sparing mastectomy and matched cases for conventional nipple-sparing mastectomy.
Propensity matching analysis is applied to reduce confounding factors.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 659
- Women who underwent nipple sparing mastectomy and immediate reconstruction
- Women with early breast cancer
- Women with germline BRCA 1/2 mutation or germline mutations in genetic susceptibility genes
- Women with interstitial mastopathy
- Women with risk-reducing mastectomy or contralateral mastectomy
- Male patients
- Women with stage IV disease at diagnosis
- Women who underwent previous breast cancer surgery
- Women who received prior radiotherapy for the ipsilateral breast
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Robotic nipple sparing mastectomy group/RNSM Robotic nipple sparing mastectomy Cases or Patients who underwent robotic nipple-sparing mastectomy and immediate reconstruction are enrolled in this arm. Robotic nipple-sparing mastectomy should be performed using robotic surgical systems. Robotic surgical systems include da Vinci S,Si, X, Xi, and SP systems. Axillary or lateral incisions are used for this procedure. Immediate reconstruction includes tissue expander insertion, direct-to-implant, latissimus dorsi flap, transverse abdominis rectus muscle flap, or deep inferior epigastric perforators flap. Cases with robotic mastectomy without immediate reconstruction are excluded. The estimated sample size for this arm is 300 cases.
- Primary Outcome Measures
Name Time Method Postoperative complication rates in 30 days Postoperative 30 days Postoperative complication rates are calculated as total number of postoperative complication cases per total operation cases.
Recurrence free survival (RFS) Postoperative 5 years Events of RFS includes locoregional recurrence, distant recurrence, and death. Contralateral breast cancer and second primary malignancy are considered to be censored data.
Clavien-Dindo grade of postoperative complications Postoperative 30 days Clavien-Dindo grade of postoperative complications is evaluated. The highest grade of postoperative complications are used for the analysis.
Nipple necrosis rates Postoperative 30 days Nipple necrosis rates are calculated as number of total nipple necrosis cases per total operation cases.
- Secondary Outcome Measures
Name Time Method Locoregional recurrence-free survival (LRFS) Postoperative 5 years In breast tumor recurrences (IBTR), regional recurrences including axillary, internal mammary, or supraclavicular lymph node recurrences, and death without any cause are events of locoregional recurrence-free survival. Five year LRFS is measured. Distant metastasis, contralateral breast cancer and second primary malignancy are considered to be censored data.
Operation times Time during operation Mastectomy time or reconstruction time
Trial Locations
- Locations (1)
Yonsei University College of Medicine
🇰🇷Seoul, Korea, Republic of